AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly's Alzheimer's Drug Label Update Gains FDA Approval
ByAinvest
Thursday, Jul 10, 2025 12:05 am ET1min read
Eli Lilly's (LLY) stock rose 2% after the FDA approved an update to Kisunla's label for Alzheimer's treatment. The new monthly dosing regimen aims to reduce adverse events by up to 41%. The updated titration plan showed a significant reduction in amyloid-related imaging abnormalities with edema (ARIA-E) at 24 and 52 weeks, while maintaining similar levels of amyloid plaque clearance and reduction in P-tau217.
July 02, 2025Eli Lilly and Company (LLY) saw its stock rise by 2% following the U.S. Food and Drug Administration's (FDA) approval of an updated label for Kisunla, a once-monthly amyloid-targeting therapy for early symptomatic Alzheimer's disease (AD). The new dosing regimen aims to reduce adverse events, particularly amyloid-related imaging abnormalities with edema (ARIA-E), by up to 41% [1].
The FDA approved the updated label, which includes a modified titration dosing schedule for Kisunla, based on results from the TRAILBLAZER-ALZ 6 study. The study showed that the new dosing regimen significantly lowered the incidence of ARIA-E at 24 and 52 weeks compared to the original dosing schedule, while maintaining similar levels of amyloid plaque clearance and reduction in P-tau217 [1].
The new dosing regimen involves a more gradual titration, shifting a single vial from the first dose to the third dose. This change resulted in lower rates of ARIA-E without compromising Kisunla's ability to reduce amyloid plaque or its once-monthly dosing potential [1].
The TRAILBLAZER-ALZ 6 study, which supports this label update, enrolled 843 participants ages 60-85 and found that the incidence of ARIA-E was 14% in patients receiving the modified titration compared to 24% for those receiving the original dosing regimen, a 41% lower relative risk at 24 weeks. At week 52, the incidence of ARIA-E was 16% in patients receiving the modified titration compared to 25% for those receiving the original dosing regimen, a 35% lower relative risk [1].
The new dosing strategy is a significant advancement for patients and their care teams, offering greater confidence in the safety of Kisunla while preserving its ability to reduce amyloid plaque [1].
References:
1. [1] https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-kisunla-donanemab-azbt-new
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet